Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Posts Q4 Loss on Higher Expenses


Rosetta Genomics this week reported its fourth-quarter financial results, posting a net loss on increased expenses.

In the quarter, the company's net loss was $4.1 million, or $0.29 per share, compared with a profit of $2 million, or $0.17 per share, in the same period a year earlier.

Revenues in the three-month period ended Dec. 31 were $119,000, compared with zero revenues in the year-ago quarter.

Marketing and business expenses, meanwhile, jumped to $1.3 million from $713,000, as general and administrative costs surged to $1.2 million from $773,000.

Research and development spending in the fourth quarter fell, however, to $1.7 million from $2.1 million, primarily due to a reduction in headcount associated with a narrowing of the company's focus (see RNAi News, 12/31/2009).

At the end of 2009, Rosetta had cash, cash equivalents, short-term bank deposits, and marketable securities totaling $10.3 million.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.